Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535359) titled 'Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer' on April 9.
Study Type: Expanded Access
Primary Sponsor: Daiichi Sankyo
Condition:
SCLC
Extensive-stage Small Cell Lung Cancer
Intervention:
Drug: Ifinatamab Deruxtecan
Recruitment Status: Not recruiting
Date of First Enrollment: August 2026
To know more, visit https://clinicaltrials.gov/study/NCT07535359
Disclaimer: Curated by HT Syndication....